ReviewFrontiers in endocrinology2026
Bone health in asthma: a twofold effect of disease and pharmacotherapy.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic inflammatory airway disease with high global prevalence. Its persistent systemic inflammation and long-term treatments pose significant risks to bone health. This article aims to systematically elucidate the mechanisms by which asthma affects bone health and the corresponding clinical management strategies. Chronic inflammation disrupts bone metabolism through immune dysregulation, pro-inflammatory cytokine release, and oxidative stress, enhancing bone resorption and suppressing formation. Disease-related physical inactivity and common vitamin D (VitD) deficiency further impair bone health by reducing mechanical loading and altering endocrine regulation. Pharmacologically, long-term or high-dose glucocorticoids (GCs) therapy significantly lowers bone mineral density and increases fracture risk. Based on these mechanisms, comprehensive management strategies include optimizing inhaled therapies and judicious use of natural medicines to limit GCs exposure. Future research should clarify molecular mechanisms of the lung-bone axis, develop risk assessment models integrating inflammatory markers and cumulative GCs exposure, and implement routine bone health monitoring for high-risk populations. Multidisciplinary collaboration among respiratory medicine, paediatrics, and orthopaedics is essential to balance asthma control with preservation of bone health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.